Background/Aims: Mammalian target of rapamycin (mTOR) is a valuable treatment target of renal cell carcinoma (RCC). Palomid 529 is a novel mTORC1/2 dual inhibitor. Methods: RCC cells were treated with different concentrations of Palomid 529. Cell survival was tested by MTT assay and clonogenicity assay. Cell proliferation was tested by BrdU ELISA assay. Cell apoptosis was tested by the Hoechst-33342 nuclei staining assay and Histone DNA ELISA assay. mTOR signaling was tested by Western blotting assay and co-immunoprecipitation ( 
Apoptosis ELISA assay
Nucleosomal DNA fragmentation is a characteristic marker of cell apoptosis. The Histone-bound DNA was tested via a specific two-site enzyme-linked immunosorbent assay (ELISA) kit (Roche, Shanghai, China). Histone DNA ELISA OD at 450 nm was recorded.
Hoechst-33342 nuclei staining of apoptotic cells
Following the Palomid 529 treatment, RCC cells were stained with Hoechst-33342 dye (Sigma). Non-apoptotic nuclei were with faint delicate chromatin staining. Nuclei with intensified Hoechst-33342 condensation/brightness (early apoptotic cells) or fragmentation (late apoptotic cells) were labeled as apoptotic cells. Apoptotic nuclei percentage was calculated, from at least 200 cells of 5 random views (1×100) of each treatment.
Western blotting assay
The lysate proteins (30 μg per lane of each treatment) were separated by 7.5-10% of SDS-PAGE gels, which were then transferred to PVDF membranes (Millipore, Wuxi, China). After blocking, the blots were incubated with primary and secondary antibodies. ECL detection kit was applied to detect the signals via x-ray films. Quantification of the protein band was through the Image J software.
Co-Immunoprecipitation (IP)
As described [30, 31] , following the applied Palomid 529 treatment, 800 μg protein lysates per sample were pre-cleared by the protein A/G Sepharose ("beads", Sigma). The pre-cleared lysates were then incubated with anti-mTOR antibody. Afterwards, 30 µL of protein A/G beads were added again for 2 hours at 4 °C. The beads were washed and tested by the Western blotting analysis [30, 31] .
Quantitative real-time PCR
The total cellular RNA was extracted by the Trizol reagents (Sigma). High Capacity cDNA Reverse Transcription Kit was applied to synthesis cDNA from 2.0 μg RNA (per sample). The Power SYBR Green RT-PCR Reagents Kit was employed to perform the quantitative real-time PCR ("qRT-PCR") via the ABI-7600 FAST PCR system (Applied Biosystems, Foster, CA). We utilized the 2 ΔΔCt method to calculate relative BRD4 mRNA expression (vs. GAPDH). BRD4 mRNA primers were described previously [32] .
shRNA-mediated gene knockdown
Two lentiviral BRD4 shRNAs, with unique and non-overlapping sequences, were purchased from Sigma (SHCLNV-NM_058243, "BRD4 shRNA-1") and Santa Cruz Biotech (sc-43639-V, "BRD4 shRNA-2"). The lentiviral vector pLKO-1 containing c-MYC shRNA-1 (targeting sequence 1567-1585) and c-MYC shRNA-2 (targeting sequence 1341-1359) were provided by Genechem (Shanghai, China). shRNA lentivirus was 
Exogenous BRD4 overexpression
The pcDNA5-Flag-BRD4-WT-puro was purchased from Addgene (Plasmid #90331, Shanghai, China). The construct was transfected to 786-O cells using Lipofectamine 2000 (Invitrogen, Shanghai, China). Cells were then subjected to 5.0 μg/mL puromycin selection for 10-12 days. Exogenous and endogenous BRD4 expression in the stable cells were tested by Western blot assay.
Xenograft model
The male severe combined immunodeficiency (SCID) mice of 4 week old, 17-18g weight, were purchased from the Experimental Animal Center of Soochow University (Suzhou, China). To establish the xenograft tumor, 786-O RCC cells (5 × 10 6 cells of each mouse) were injected subcutaneously (s.c.) to the right flanks. Tumors were established within three weeks with volume around 100 mm 3 . Mice (n=10 each group) were treated once every two days. Mice body weight and bi-dimensional tumor measurements were taken every 6 days for a total of 42 days. Tumor volume was measured as described [27] . The animal protocol was approved by the Institutional Animal Care and Use Committee (IACUC) and ERB of Soochow University (Suzhou, China). Mice in this study were observed on daily basis. Humane endpoints were applied to reduce suffering.
Statistics
Data were expressed as the mean ± SD (standard deviation). Comparisons between groups were performed via one-way ANOVA (SPSS 18.0). p values < 0.05 were considered statistically significant. IC-50 was calculated by SPSS 18.0. (Fig. 1A and B) .
Results

Palomid
The potential effect of Palomid 529 on cell proliferation was analyzed. BrdU incorporation ELISA assay [33] was performed, and results show that Palomid 529 dosedependently inhibited 786-O cell proliferation (Fig. 1C) . Apoptosis activation could be a primary mechanism of viability reduction and/or proliferation inhibition. As shown in Fig. 1D , Palomid 529 at 1-10 μM significantly increased the Histone-bound DNA ELISA OD, suggesting apoptosis activation. Additionally, the percentage of apoptotic nuclei was increased in Palomid 529 (1-10 μM)-treated 786-O cells (Fig. 1E) . Palomid 529 also induced cleavages of both PARP (Poly (ADP-ribose) polymerases) and caspase-9 in 786-O cells (Fig.  1F) . Palomid 529 at 0.1 μM had no significant effect on cell apoptosis (Fig. 1D-F [8, 10] . By performing the Western blotting assay, we show that Palomid 529 dose-dependently inhibited phosphorylation of S6 (Ser-235/236) and AKT (at Ser-473) in 786-O cells ( Fig.  2A) . AKT Thr-308 phosphorylation was not affected ( Fig. 2A) , neither did ERK activation ("p-ERK1/2") ( Fig. 2A) .
By performing the co-immunoprecipitation ("IP") assay, we show that Palomid 529 (5 μM, 1 hour) disrupted mTOR-Raptor association (the mTORC1 assembling [34] ) and mTORRictor association (the mTORC2 assembling [11, 12] ) in 786-O cells ( 
BRD4 inhibitors facilitate Palomid 529-induced 786-O cell apoptosis
Recent studies have proposed a chemo-resistance activity of BRD4 [35, 36] . To test if BRD4 plays a similar role to Palomid 529, the BRD4 inhibitors were applied, including JQ1 [37, 38] , MS436 [39] and CPI203 [40] . The BRD4 inhibitors significantly enhanced Palomid 529 (5 μM)-induced 786-O cell viability reduction (Fig. 3A) and apoptosis (Hoechst nuclei staining assay in Fig. 3B and Histone DNA apoptosis ELISA assay in Fig. 3C ). Treatment with the BRD4 inhibitors alone only resulted in minor viability reduction (Fig. 3A ) and apoptosis 
BRD4 shRNA sensitizes Palomid 529-induced cytotoxicity in 786-O cells
To exclude the possible off-target effect of the BRD4 inhibitors, shRNA strategy was employed to silence BRD4. Two different BRD4 shRNAs ("-1/-2") were utilized, which led to over 90% BRD4 mRNA reduction in the stable 786-O cells (Fig. 4A) . Western blotting assay results further confirmed significant BRD4 silencing by the targeted-shRNAs (Fig. 4B ). BRD4 is essential for c-Myc expression [41] , the latter is a key resistance factor in RCC cells [42] . Here, BRD4 silencing also led to significant c-Myc downregulation in 786-O cells (Fig. 4B ). BRD4 shRNA alone only induced minor cell viability reduction (Fig. 4C) and apoptosis (Fig.  4D) . Importantly, Palomid 529-induced viability reduction ( 
To study the potential effect of c-Myc on Palomid 529-induced activity in RCC cells, shRNA method was applied again to knockdown c-Myc. As shown, each of the two applied c-Myc shRNAs ("-1/-2") led to over 95% c-Myc protein reduction in 786-O cells (Fig. 4E) . Palomid 529 treatment again failed to affect c-Myc expression (Fig. 4E) . Importantly, c-Myc silencing dramatically enhanced Palomid 529-induced 786-O cell viability reduction (Fig.  4F) and apoptosis (Fig. 4G) . c-Myc shRNAs alone only induced minor cell viability reduction (Fig. 4F) and apoptosis (Fig. 4G) 
BRD4 over-expression inhibits Palomid 529-induced 786-O cell apoptosis
A BRD4 expression construct was transfected to 786-O cells. Puromycin was applied to select stable cells. As shown in Fig. 5A , BRD4 mRNA level was significantly increased in cells with the construct (Fig. 5A) . Western blotting assay results in Fig. 5B further confirmed expression of exogenous BRD4 (tagged with Flag) in the stable cells. c-Myc upregulation was detected as well in BRD4 over-expression cells (Fig. 5B) . Significantly, Palomid 529-induced 786-O cell viability reduction (Fig. 5C) and apoptosis (Fig. 5D) were significantly inhibited in BRD4 over-expression cells. Thus, BRD4 over-expression inhibits Palomid 529-induced 786-O cell apoptosis.
Palomid 529 is cytotoxic to the primary human RCC cells
We next studied the potential effect of Palomid 529 in the primary human RCC cells. A total of four different patient-derived primary human RCC cells were tested: namely "L1/L2/L3/L4". Among them, BRD4 protein expression was high in the "L1/L2" RCC cells, but relatively low in the "L3/L4" RCC cells (Fig. 6A ). mTORC1 (reflected by "p-S6") and mTORC2 (reflected by "p-AKT Ser473") activation were high in "L1/L2/L3" RCC cells, but low in the "L4" RCC cells (Fig. 6A) . Treatment with Palomid 529 dose-dependently inhibited cell viability in all the primary cancer cells (Fig. 6B ). Yet, its cytotoxicity was most potent Fig. 6B ), which had lowest BRD4 expression but highest mTORC1/2 activation (Fig. 6A) . "L2" RCC cells, with highest BRD4 expression (Fig. 6A) , were resistant to Palomid 529, (IC-50 over 50 μM, Fig. 6B ). When analyzing cell apoptosis, we show that Palomid 529 (5 μM) induced significant apoptosis in "L3" RCC cells (Fig. 6C) . Thus, Palomid 529 is cytotoxic to the primary human RCC cells. Its sensitivity is negatively correlated with BRD4 expression in the primary cancer cells.
JQ1 facilitates Palomid 529-induced anti-tumor activity in vivo
The potential effect of Palomid 529 in vivo was tested. 786-O cells (5×10 6 cells per mouse) were inoculated via s.c. injection to the severe combined immunodeficiency (SCID) mice. Tumor growth curve results show that Palomid 529 (100 mg/kg/2 d, i.p., for 18 days) [20, 21] administration significantly inhibited 786-O xenograft tumor growth in SCID mice (Fig. 7A) . The estimated daily tumor growth was calculated by: (tumor volume at Day-42-tumor volume at Day-0)/42. Results show again that Palomid 529 administration inhibited 786-O xenograft tumor growth. At Day-42, the tumors in Palomid 529 treatment group were significantly lighter than the vehicle control tumors (Fig. 7C) . Remarkably, co-administration of JQ1 (50 mg/kg/2 d, i.p., for 18 days) [43] significantly enhanced Palomid 529-induced anti-786-O tumor activity in vivo (Fig. 7A-C) . Treatment with JQ1 alone exerted only minor inhibition on 786-O tumor growth (Fig. 7A-C) .
The body weights of the experimental animals were not significantly different between the groups (Fig. 7D) , indicating that the single or combination treatments were relatively safe to the animals. At Day-6, three hours after the drug administration, one tumor of each group was isolated. Expression of signaling proteins in tumor lysates were tested. As shown in Fig. 7E , administration of Palomid 529 led to dramatic inhibition of p-S6 (Ser-235/236) and p-AKT (Ser-473), indicating mTORC1/2 dual inhibition in vivo. Co-administration of JQ1 failed to affect p-AKT nor p-S6 in the tumor tissues (Fig. 7E) . 
Discussion
Inhibition, silencing or loss-of-function mutation of mTOR can efficiently induce RCC cell death and apoptosis. Everolimus and other mTORC1 inhibitors have been approved by FDA for the treatment of certain advanced RCCs [3, 5] . The clinical application of these mTORC1 inhibitors, however, could have several drawbacks (see Introduction). Recent studies have implied that concurrent blockage of mTORC1 and mTORC2 is more efficient than mTORC1 inhibitors in inhibiting RCC cells [27, 29] . One possible reason could be that mTORC2 is as important as mTORC1 for RCC cell progression [28, 44, 45] .
Here, we show that Palomid 529 not only disassembled mTORC1 (mTOR-Raptor complex) and mTORC2 (mTOR-Rictor complex), but also de-phosphorylated mTORC1/2 substrates in 786-O RCC cells. Palomid 529 exerted cytotoxic, anti-proliferative and proapoptotic activities to 786-O cells and the primary human RCC cells. In vivo, Palomid 529 i.p. administration potently inhibited 786-O xenograft tumor growth in SCID mice. Thus, Palomid 529 could be further tested as a promising anti-RCC agent.
Recent studies have implied that BRD4 is essential for activation and expression of several key oncogenes. It can promote cell proliferation, cell-cycle progression, survival and apoptosis resistance [46] . Several of these genes have been indentified, including cyclin D1, Bcl-2 and c-Myc [38, [47] [48] [49] [50] [51] . Our results show that BRD4 silencing by targeted shRNAs led to c-Myc downregulation in 786-O cells. Reversely, c-Myc upregulation was detected in BRD4 over-expression cells. Thus, BRD4 is required for c-Myc expression in RCC cells.
We propose that BRD4 could be a primary resistant factor of Palomid 529. First, pharmacologic inhibition of BRD4 enhanced Palomid 529-induced 786-O cell death Inhibition of BRD4 could be a fine strategy to sensitize Palomid 529 in RCC cells. Previous studies have established synergistic to additive effects between mTORC1 inhibitors and bromodomain protein inhibition in various human cancers [52] [53] [54] . For example, Lee et al., reported the synergistic anti-osteosarcoma activity by the BRD4 inhibitor JQ1 and rapamycin [54] . Berenguer-Daize et al., reported that OTX015 (a novel BET inhibitor) and the mTORC1 inhibitor everolimus synergisticly inhibited glioblastoma cell growth [52] . In the breast cancer cells, BRD4-Myc inhibition could significantly sensitize everolimus [53] . Therefore, BRD4-dependent resistance in RCC cells could be a primarily mTORC1-dependent effect, although the underlying mechanisms warrant further characterizations.
Conclusion
Palomid 529 blocks mTORC1/2 activation, inhibiting RCC cell growth in vitro and in vivo. BRD4 could be the primary resistance factor of Palomid 529 in RCC cells. Everolimus has been approved by FDA to treat patients with advanced kidney cancer after failure of either sunitinib or sorafenib treatment [3, 5] . Our results suggest that Palomid 529 might possibly be an alternative of rapalogs for RCC treatment.
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